{"url":"https://lda.senate.gov/api/v1/filings/b6fe0721-f820-41ec-a6bd-e7b5cfcd7df7/","filing_uuid":"b6fe0721-f820-41ec-a6bd-e7b5cfcd7df7","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/b6fe0721-f820-41ec-a6bd-e7b5cfcd7df7/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-07-02T16:47:26-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1177 22nd Street NW","registrant_address_2":"Unit 4A","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20037","registrant":{"id":401108688,"url":"https://lda.senate.gov/api/v1/registrants/401108688/","house_registrant_id":56560,"name":"AEGIS LLC","description":null,"address_1":"1177 22nd Street NW","address_2":"Unit 4A","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20037","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 301-928-4388","dt_updated":"2026-07-05T15:52:54.241266-04:00"},"client":{"id":60968,"url":"https://lda.senate.gov/api/v1/clients/60968/","client_id":60968,"name":"TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS","general_description":"Biopharmaceutical company.","client_government_entity":null,"client_self_select":false,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2024-07-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"ADHD treatment. Implementation of the Infrastructure Investment and Jobs Act (or bipartisan infrastructure law). Traffic safety (distracted and impaired driving). Issues related to FDA approval. Patient access to non-opioid pain medicines. NO PAIN Act implementation. H.R.1227 / S.475: Alternatives to PAIN Act. Most-Favored Nation (MFN) International reference pricing. Make America Healthy Again (MAHA) Commission.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147132,"prefix":"ms","prefix_display":"MS.","first_name":"ANNE","nickname":null,"middle_name":"ELIZABETH","last_name":"ESPOSITO","suffix":null,"suffix_display":null},"covered_position":"Health Policy Coordinator, Energy and Commerce Committee; Health Policy Advisor, Health Subcommittee (Chairman Bilirakis)","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}